Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2001 | 03-2001 | 12-2000 | 09-2000 | 06-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,712 | 461 | -5,917 | -3,454 | -2,867 |
| Depreciation Amortization | 457 | 230 | 1,233 | 848 | 591 |
| Accounts receivable | 1,591 | -3,730 | -1,505 | 51 | -330 |
| Other Working Capital | 995 | -4,512 | -4,438 | -2,925 | -2,161 |
| Other Operating Activity | 342 | 4,326 | 3,044 | 1,101 | 1,119 |
| Operating Cash Flow | $9,097 | $-3,226 | $-7,583 | $-4,380 | $-3,648 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 6,429 | 5,339 | -11,496 | -8,736 | -8,664 |
| PPE Investments | -685 | -332 | -1,325 | -867 | -171 |
| Investing Cash Flow | $5,744 | $5,007 | $-12,821 | $-9,603 | $-8,836 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3 | -2 | -105 | -104 | -101 |
| Common Stock Issued | 570 | 199 | 1,926 | 1,579 | 1,422 |
| Financing Cash Flow | $567 | $197 | $1,821 | $1,475 | $1,321 |
| Beginning Cash Position | 5,629 | 5,629 | 24,213 | 24,213 | 24,213 |
| End Cash Position | 21,036 | 7,607 | 5,629 | 11,705 | 13,050 |
| Net Cash Flow | $15,407 | $1,978 | $-18,584 | $-12,507 | $-11,162 |
| Free Cash Flow | |||||
| Operating Cash Flow | 9,097 | -3,226 | -7,583 | -4,380 | -3,648 |
| Capital Expenditure | -685 | -332 | -1,325 | -867 | -171 |
| Free Cash Flow | 8,412 | -3,558 | -8,908 | -5,246 | -3,820 |